JP2016526909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016526909A5 JP2016526909A5 JP2016531860A JP2016531860A JP2016526909A5 JP 2016526909 A5 JP2016526909 A5 JP 2016526909A5 JP 2016531860 A JP2016531860 A JP 2016531860A JP 2016531860 A JP2016531860 A JP 2016531860A JP 2016526909 A5 JP2016526909 A5 JP 2016526909A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cysteine
- substituted
- amino acid
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 235000001014 amino acid Nutrition 0.000 claims 8
- 235000018417 cysteine Nutrition 0.000 claims 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020160475A JP7344858B2 (ja) | 2013-07-31 | 2020-09-25 | Ｆｃ含有ポリペプチドの安定化 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361860800P | 2013-07-31 | 2013-07-31 | |
| US61/860,800 | 2013-07-31 | ||
| PCT/US2014/048908 WO2015017548A2 (en) | 2013-07-31 | 2014-07-30 | Stabilization of fc-containing polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020160475A Division JP7344858B2 (ja) | 2013-07-31 | 2020-09-25 | Ｆｃ含有ポリペプチドの安定化 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016526909A JP2016526909A (ja) | 2016-09-08 |
| JP2016526909A5 true JP2016526909A5 (enExample) | 2017-09-07 |
Family
ID=52432568
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531860A Pending JP2016526909A (ja) | 2013-07-31 | 2014-07-30 | Ｆｃ含有ポリペプチドの安定化 |
| JP2020160475A Active JP7344858B2 (ja) | 2013-07-31 | 2020-09-25 | Ｆｃ含有ポリペプチドの安定化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020160475A Active JP7344858B2 (ja) | 2013-07-31 | 2020-09-25 | Ｆｃ含有ポリペプチドの安定化 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160193295A1 (enExample) |
| EP (1) | EP3027647A4 (enExample) |
| JP (2) | JP2016526909A (enExample) |
| KR (3) | KR20160034404A (enExample) |
| CN (1) | CN105658664A (enExample) |
| AU (3) | AU2014296215A1 (enExample) |
| BR (1) | BR112016002219A2 (enExample) |
| CA (1) | CA2919076C (enExample) |
| CL (1) | CL2016000232A1 (enExample) |
| EA (1) | EA035319B1 (enExample) |
| HK (1) | HK1224203A1 (enExample) |
| IL (1) | IL243690B (enExample) |
| MX (2) | MX2016001165A (enExample) |
| SG (1) | SG11201600734YA (enExample) |
| WO (1) | WO2015017548A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6254146B2 (ja) | 2012-03-27 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 代謝障害を治療するための組成物および方法 |
| KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
| UA123432C2 (uk) | 2014-07-30 | 2021-04-07 | Нджм Біофармасьютікалз, Інк. | Димер та спосіб його застосування для лікування метаболічних розладів |
| MD20170035A2 (ro) | 2014-10-31 | 2017-09-30 | Ngm Biopharmaceuticals Inc | Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| CN117964732A (zh) | 2015-08-07 | 2024-05-03 | Alx肿瘤生物技术公司 | 具有SIRP-α结构域或其变体的构建体 |
| EP3463451A1 (en) | 2016-05-26 | 2019-04-10 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
| EP3474884A4 (en) | 2016-06-22 | 2020-08-19 | Alkermes, Inc. | COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10 |
| MX2019007611A (es) * | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| WO2018144784A1 (en) * | 2017-02-01 | 2018-08-09 | Smet Pharmaceutical Inc. | MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES |
| IL271837B2 (en) * | 2017-07-07 | 2024-01-01 | Hanmi Pharm Ind Co Ltd | Novel therapeutic enzyme fusion protein and use thereof |
| JP2020531002A (ja) | 2017-08-15 | 2020-11-05 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学用ｉｇｇ ｆｃ変異体 |
| CN107540748B (zh) * | 2017-09-15 | 2020-07-14 | 北京伟杰信生物科技有限公司 | 长效重组猪fsh融合蛋白及其制备方法与应用 |
| BR112020012346A2 (pt) * | 2017-12-22 | 2020-11-24 | Hanmi Pharm. Co., Ltd. | proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma |
| TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
| IL280467B2 (en) | 2018-08-03 | 2025-03-01 | Amgen Res Munich Gmbh | Antibody constructs for CLDN18.2 and CD3 |
| KR102200773B1 (ko) * | 2018-09-19 | 2021-01-12 | 주식회사 바이오앱 | 돼지의 Fc 단편과 융합된 항원 및 이를 포함하는 백신 조성물 |
| KR102148405B1 (ko) * | 2018-09-19 | 2020-08-27 | 주식회사 바이오앱 | 돼지의 Fc 단편을 포함하는 재조합 벡터 및 상기 벡터를 이용한 재조합 단백질의 제조 방법 |
| US10947278B2 (en) * | 2018-09-19 | 2021-03-16 | Bioapplications Inc. | Recombinant vector comprising porcine FC fragment and preparation method of recombinant protein using thereof |
| US20220144916A1 (en) * | 2019-02-12 | 2022-05-12 | Board Of Regents, The University Of Texas System | High affinity engineered t-cell receptors targeting cmv infected cells |
| AU2020282791A1 (en) | 2019-05-31 | 2021-12-09 | ALX Oncology Inc. | Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor |
| US20220259329A1 (en) | 2019-06-07 | 2022-08-18 | Amgen Inc. | Bispecific binding constructs |
| CR20220107A (es) * | 2019-09-18 | 2022-04-25 | Novartis Ag | Proteínas de fusión nkg2d y sus usos |
| PT4065585T (pt) | 2019-11-25 | 2025-09-30 | Alkermes Inc | Compostos macrocíclicos substituídos e métodos de tratamento relacionados |
| BR112022008817A2 (pt) | 2019-11-27 | 2022-07-26 | Alx Oncology Inc | Terapias combinadas para tratamento de câncer |
| AU2020400805B2 (en) * | 2019-12-11 | 2024-03-28 | Lg Chem, Ltd. | Fusion polypeptide comprising GDF15 and polypeptide region capable of O-glycosylation |
| US20230093169A1 (en) | 2020-01-22 | 2023-03-23 | Amgen Research (Munch) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
| JP7481856B2 (ja) * | 2020-02-25 | 2024-05-13 | シスメックス株式会社 | 改変抗体及びその製造方法、並びに抗体の熱安定性を向上させる方法 |
| CN111285936A (zh) * | 2020-03-11 | 2020-06-16 | 北京双赢科创生物科技有限公司 | 靶向肿瘤的酸性敏感纳米肽段及其应用 |
| EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
| EP4153633A1 (en) | 2020-05-19 | 2023-03-29 | Amgen Inc. | Mageb2 binding constructs |
| CN116096736A (zh) * | 2020-08-14 | 2023-05-09 | 武汉友微生物技术有限公司 | 新型冠状病毒rbd融合蛋白 |
| AU2021329742B2 (en) * | 2020-08-21 | 2025-12-11 | Fatiabgen Inc. | Antibody fragment consisting of heavy chain and light chain constant regions in which gamma constant region (CΓ1) and epsilon constant region (CE2-4) are fused, and use thereof |
| CN114426974B (zh) * | 2020-10-29 | 2023-11-21 | 洛阳普泰生物技术有限公司 | 特异性结合非洲猪瘟病毒CD2v蛋白的抗体或抗体片段 |
| MX2023005063A (es) * | 2020-11-02 | 2023-05-12 | Attralus Inc | Proteinas de fusion sap fc y metodos de uso. |
| AU2021374036A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
| EP4256336A1 (en) * | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| CN115925984A (zh) * | 2021-08-24 | 2023-04-07 | 广东东阳光药业有限公司 | Gdf15融合蛋白及其用途 |
| CN116064562A (zh) * | 2022-10-28 | 2023-05-05 | 江南大学 | 玉米赤霉烯酮的真核表达单链抗体以及全长抗体的制备方法以及用途 |
| CN119080948B (zh) * | 2023-04-17 | 2025-05-27 | 北京康乐卫士生物技术股份有限公司 | 带状疱疹病毒疫苗的嵌合抗原及其应用 |
| WO2025036564A1 (de) * | 2023-08-17 | 2025-02-20 | Gottfried Wilhelm Leibniz Universität Hannover (Luh) | Nukleinsäuresequenz, vektor, screening-verfahren und verfahren zur herstellung von rekombinanten antikörpern |
| WO2025162458A1 (zh) * | 2024-02-04 | 2025-08-07 | 南通壹宸生物医药科技有限公司 | 融合抗体及其制备和应用 |
| CN118344462B (zh) * | 2024-06-18 | 2024-11-08 | 苏州易合医药有限公司 | 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品 |
| CN119613573B (zh) * | 2025-02-14 | 2025-05-30 | 浙江大学 | 一种CD40L-Fc融合蛋白、基因片段、重组质粒、重组细胞以及制备方法和用途 |
| CN119735654B (zh) * | 2025-02-27 | 2025-07-01 | 浙江海隆生物科技股份有限公司 | 一种牛副流感病毒的亚单位hn蛋白制备方法和应用 |
| CN120623322B (zh) * | 2025-08-14 | 2025-12-05 | 成都蓉生药业有限责任公司 | 一种人IgG Fc变体、基因片段、表达载体、宿主细胞、IgG抗体及人IgG Fc变体制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| DK0979281T3 (da) * | 1997-05-02 | 2005-11-21 | Genentech Inc | Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele |
| US7951917B1 (en) * | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754209B2 (en) * | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| AU2005282700A1 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| AU2006317242A1 (en) * | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| AU2010321720B2 (en) * | 2009-11-23 | 2017-03-02 | Amgen Inc. | Monomeric antibody Fc |
| MX379481B (es) * | 2010-12-06 | 2025-03-11 | Seagen Inc | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer |
-
2014
- 2014-07-30 MX MX2016001165A patent/MX2016001165A/es unknown
- 2014-07-30 JP JP2016531860A patent/JP2016526909A/ja active Pending
- 2014-07-30 KR KR1020167004786A patent/KR20160034404A/ko not_active Ceased
- 2014-07-30 BR BR112016002219A patent/BR112016002219A2/pt not_active Application Discontinuation
- 2014-07-30 KR KR1020237032656A patent/KR20230141929A/ko not_active Ceased
- 2014-07-30 AU AU2014296215A patent/AU2014296215A1/en not_active Abandoned
- 2014-07-30 CN CN201480046222.5A patent/CN105658664A/zh active Pending
- 2014-07-30 US US14/909,431 patent/US20160193295A1/en not_active Abandoned
- 2014-07-30 EA EA201690299A patent/EA035319B1/ru not_active IP Right Cessation
- 2014-07-30 HK HK16112553.6A patent/HK1224203A1/zh unknown
- 2014-07-30 CA CA2919076A patent/CA2919076C/en active Active
- 2014-07-30 WO PCT/US2014/048908 patent/WO2015017548A2/en not_active Ceased
- 2014-07-30 KR KR1020257032842A patent/KR20250152665A/ko active Pending
- 2014-07-30 SG SG11201600734YA patent/SG11201600734YA/en unknown
- 2014-07-30 EP EP14832297.7A patent/EP3027647A4/en active Pending
- 2014-07-30 IL IL243690A patent/IL243690B/en unknown
-
2016
- 2016-01-27 MX MX2022008013A patent/MX2022008013A/es unknown
- 2016-01-28 CL CL2016000232A patent/CL2016000232A1/es unknown
-
2019
- 2019-03-08 US US16/297,494 patent/US20190192628A1/en active Pending
-
2020
- 2020-01-17 AU AU2020200329A patent/AU2020200329A1/en not_active Abandoned
- 2020-09-25 JP JP2020160475A patent/JP7344858B2/ja active Active
-
2022
- 2022-02-22 AU AU2022201204A patent/AU2022201204B2/en active Active
-
2025
- 2025-01-17 US US19/030,935 patent/US20250325631A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016526909A5 (enExample) | ||
| ZA202409972B (en) | Fcrn antagonists and methods of use | |
| JP2017512063A5 (enExample) | ||
| EP4417624A3 (en) | Antibodies comprising chimeric constant domains | |
| EA201190326A1 (ru) | Полипептиды гормона роста и способы их получения и применения | |
| JP2017509335A5 (enExample) | ||
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| PH12020551134A1 (en) | Fc variants with enhanced binding to fcrn and prolonged half-life | |
| MX2017006866A (es) | Pares de unión para producción de péptidos. | |
| EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
| WO2016057769A3 (en) | Glycoengineered antibody drug conjugates | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| WO2015023891A3 (en) | Factor viii-xten fusions and uses thereof | |
| EA201790976A1 (ru) | Терапевтические вакцины против hpv16 | |
| WO2013142859A3 (en) | Fusion proteins of superfolder green fluorescent protein and use thereof | |
| WO2014080401A3 (en) | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| RU2016140244A (ru) | Способы и композиции для секреции гетерологичных полипептидов | |
| UA117493C2 (uk) | Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання | |
| EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
| BR112021022405A2 (pt) | Domínios variantes para multimerização de proteínas e separação das mesmas | |
| NZ760008A (en) | Uti fusion proteins | |
| GB2543713A (en) | Polymeric proteins and uses thereof | |
| JP2017526625A5 (enExample) |